However, the message has not impacted clinicians as well as it should; in the IMPROVE-HF registry, only 80% of eligible patients with LV dysfunction were prescribed an ACE inhibitor/ARB at baseline.211 6.7.3. Angiotensin Receptor Blockers Compared with placebo, the ARBs losartan255 and irbesar- significantly reduced the incidence of HF in patients with type 2 diabetes mellitus and nephropathy. The VALIANT trial found valsartan to be noninferior to captopril, although it did not show superiority.61 The Evaluation of Losartan in the Elderly (ELITE) II trial compared the efficacy of losartan 50 mg/d with captopril 150 mg/d and found that the rates of all- cause mortality and sudden death or resuscitated arrests for the losartan group were not significantly different from those for the captopril group.257 The Valsartan Heart Failure Trial (Val-HeFT) assessed the efficacy of valsartan at doses up to 320 mg/d added to standard therapy for reducing morbidity and mortality in patients with HF.258 Patients receiving val- sartan demonstrated a 13.2% reduction in the combined end point of cardiovascular mortality and morbidity compared with patients receiving placebo. 